$RGLS
Regulus Therapeutics Inc.

2018 Q2 Form 10-Q Financial Statement

#000162828018006555 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $18.00K $18.00K $18.00K
YoY Change 0.0% 0.0% -96.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.350M $3.770M $3.960M
YoY Change -52.55% -4.8% -22.35%
% of Gross Profit
Research & Development $10.01M $11.83M $15.75M
YoY Change -29.87% -24.91% -6.04%
% of Gross Profit
Depreciation & Amortization $560.0K $563.0K $699.0K
YoY Change -15.15% -19.46% 66.83%
% of Gross Profit
Operating Expenses $13.36M $15.60M $19.71M
YoY Change -37.37% -20.85% -9.86%
Operating Profit -$13.34M -$15.58M -$19.69M
YoY Change -37.4% -20.87% -7.88%
Interest Expense $621.0K $605.0K $546.0K
YoY Change 2.99% 10.81% 2175.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$13.85M -$16.02M -$20.03M
YoY Change -36.29% -19.98% -5.6%
Income Tax $0.00 $1.000K -$4.000K
% Of Pretax Income
Net Earnings -$13.85M -$16.03M -$20.02M
YoY Change -35.92% -19.96% -5.59%
Net Earnings / Revenue -76927.78% -89027.78% -111227.78%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.594M -$1.849M -$4.529M
COMMON SHARES
Basic Shares Outstanding 104.3M shares 104.0M shares 52.93M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.90M $45.10M $57.50M
YoY Change -17.96% -21.57% -45.29%
Cash & Equivalents $13.49M $10.06M $14.89M
Short-Term Investments $19.40M $35.10M $42.60M
Other Short-Term Assets $1.536M $1.451M $3.534M
YoY Change -49.11% -58.94% 761.95%
Inventory
Prepaid Expenses $4.655M $4.655M $6.212M
Receivables $200.0K $200.0K $400.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $39.23M $51.43M $67.65M
YoY Change -21.45% -23.98% -41.56%
LONG-TERM ASSETS
Property, Plant & Equipment $8.906M $9.305M $11.27M
YoY Change -17.18% -17.44% 2.87%
Goodwill
YoY Change
Intangibles $705.0K $726.0K $920.0K
YoY Change -14.34% -21.09% -13.94%
Long-Term Investments
YoY Change
Other Assets $328.0K $620.0K $335.0K
YoY Change -3.53% 85.07% -5.37%
Total Long-Term Assets $9.939M $10.65M $12.53M
YoY Change -16.59% -14.96% 1.18%
TOTAL ASSETS
Total Short-Term Assets $39.23M $51.43M $67.65M
Total Long-Term Assets $9.939M $10.65M $12.53M
Total Assets $49.17M $62.08M $80.17M
YoY Change -20.51% -22.57% -37.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.468M $4.396M $4.509M
YoY Change 11.57% -2.51% 24.49%
Accrued Expenses $2.090M $3.371M $4.690M
YoY Change -55.69% -28.12% -14.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $19.90M $19.90M
YoY Change
Total Short-Term Liabilities $30.80M $30.93M $10.58M
YoY Change 176.89% 192.46% -3.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $19.80M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $437.0K $438.0K $214.0K
YoY Change 54.42% 104.67% -97.27%
Total Long-Term Liabilities $437.0K $438.0K $214.0K
YoY Change 54.42% 104.67% -97.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.80M $30.93M $10.58M
Total Long-Term Liabilities $437.0K $438.0K $214.0K
Total Liabilities $38.74M $39.20M $41.45M
YoY Change -7.47% -5.41% 98.22%
SHAREHOLDERS EQUITY
Retained Earnings -$373.9M -$344.0M -$294.0M
YoY Change 18.48% 17.02% 38.2%
Common Stock $384.4M $383.0M $332.8M
YoY Change 14.52% 15.1% 3.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.43M $22.88M $38.73M
YoY Change
Total Liabilities & Shareholders Equity $49.17M $62.08M $80.17M
YoY Change -20.51% -22.57% -37.43%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$13.85M -$16.03M -$20.02M
YoY Change -35.92% -19.96% -5.59%
Depreciation, Depletion And Amortization $560.0K $563.0K $699.0K
YoY Change -15.15% -19.46% 66.83%
Cash From Operating Activities -$12.21M -$15.60M -$18.68M
YoY Change -29.54% -16.48% 109.18%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $139.0K
YoY Change -100.0% -100.0% -64.81%
Acquisitions
YoY Change
Other Investing Activities $15.71M $11.44M $18.50M
YoY Change 5.01% -38.16% 53.02%
Cash From Investing Activities $15.71M $11.44M $18.36M
YoY Change 4.87% -37.7% 57.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $208.0K $265.0K
YoY Change -21.51% -27.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -70.00K $701.0K $268.0K
YoY Change 161.57% -49.24%
NET CHANGE
Cash From Operating Activities -12.21M -$15.60M -$18.68M
Cash From Investing Activities 15.71M $11.44M $18.36M
Cash From Financing Activities -70.00K $701.0K $268.0K
Net Change In Cash 3.430M -$3.462M -$52.00K
YoY Change -245.96% 6557.69% -101.58%
FREE CASH FLOW
Cash From Operating Activities -$12.21M -$15.60M -$18.68M
Capital Expenditures $0.00 $0.00 $139.0K
Free Cash Flow -$12.21M -$15.60M -$18.82M
YoY Change -29.63% -17.09% 101.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001505512
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1985000 USD
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1116000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3959000 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19995000 USD
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16018000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3773000 USD
CY2017Q4 us-gaap Debt Current
DebtCurrent
19859000 USD
CY2018Q1 us-gaap Debt Current
DebtCurrent
19874000 USD
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16024000 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8072000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
381104000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20025000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
104000 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
104000 USD
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17724699 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
103955147 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104319552 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
103955147 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104319552 shares
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
7772000 USD
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1921000 USD
CY2018Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
60000 USD
CY2018Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
77000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
699000 USD
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
563000 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
104319552 shares
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-134000 USD
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-127000 USD
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
REGULUS THERAPEUTICS INC.
CY2018Q1 dei Trading Symbol
TradingSymbol
RGLS
CY2018Q1 rgls Cashand Cash Equivalentsand Marketable Securities
CashandCashEquivalentsandMarketableSecurities
45100000 USD
CY2017Q1 rgls Proceeds From Capital Lease Financing
ProceedsFromCapitalLeaseFinancing
0 USD
CY2018Q1 rgls Proceeds From Capital Lease Financing
ProceedsFromCapitalLeaseFinancing
492000 USD
CY2017Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
373000 USD
CY2018Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
188000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5743000 USD
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4396000 USD
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-107000 USD
CY2018Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-47000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2995000 USD
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3371000 USD
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
382939000 USD
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2381000 USD
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1627000 USD
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1824296 shares
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8108448 shares
CY2017Q4 us-gaap Assets
Assets
77809000 USD
CY2018Q1 us-gaap Assets
Assets
62079000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
66736000 USD
CY2018Q1 us-gaap Assets Current
AssetsCurrent
51428000 USD
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
46555000 USD
CY2018Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
35077000 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
77000 USD
CY2018Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
70000 USD
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
46632000 USD
CY2018Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
35147000 USD
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000 USD
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14941000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14889000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13519000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10057000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-52000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3462000 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4000 USD
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000 USD
CY2017Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
CY2018Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1218000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-185000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1331000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1347000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-818000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
377000 USD
CY2017Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-5000 USD
CY2018Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-408000 USD
CY2017Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1012000 USD
CY2018Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-868000 USD
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-627000 USD
CY2018Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-26000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
660000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-128000 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
775000 USD
CY2018Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
726000 USD
CY2017Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
214000 USD
CY2018Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
164000 USD
CY2017Q1 us-gaap Interest Expense
InterestExpense
546000 USD
CY2018Q1 us-gaap Interest Expense
InterestExpense
605000 USD
CY2017Q1 us-gaap Interest Paid
InterestPaid
465000 USD
CY2018Q1 us-gaap Interest Paid
InterestPaid
506000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
42593000 USD
CY2018Q1 us-gaap Liabilities
Liabilities
39203000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77809000 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62079000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32600000 USD
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
30933000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
268000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
701000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18360000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11439000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18680000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15602000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-20021000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-16025000 USD
CY2017Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0 USD
CY2018Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
191000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
19711000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
15601000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19693000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15583000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1506000 USD
CY2018Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1451000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
590000 USD
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
620000 USD
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
26000 USD
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000 USD
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2018000 USD
CY2018Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2176000 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2018Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
438000 USD
CY2017Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
135000 USD
CY2018Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
93000 USD
CY2017Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
16000 USD
CY2018Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
139000 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2017Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
2265000 USD
CY2018Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4783000 USD
CY2018Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4655000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
265000 USD
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
208000 USD
CY2017Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
20780000 USD
CY2018Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
11439000 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000 USD
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9708000 USD
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9305000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15752000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11828000 USD
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1300000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345858000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-360040000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-344014000 USD
CY2017Q1 us-gaap Revenues
Revenues
18000 USD
CY2018Q1 us-gaap Revenues
Revenues
18000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2381000 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1627000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
269000 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.65
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3655000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10649000 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14030591 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14031000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.44
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.60
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.38
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.24
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
46555000 USD
CY2018Q1 us-gaap Short Term Investments
ShortTermInvestments
35077000 USD
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4000 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
35216000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
22876000 USD
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52990383 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
104018273 shares
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001628280-18-006555-index-headers.html Edgar Link pending
0001628280-18-006555-index.html Edgar Link pending
0001628280-18-006555.txt Edgar Link pending
0001628280-18-006555-xbrl.zip Edgar Link pending
ex-101xhaganannualsalaryin.htm Edgar Link pending
ex-102xwrightannualsalaryi.htm Edgar Link pending
ex-103xdeegannualsalaryinc.htm Edgar Link pending
ex-104xchevallardannualsal.htm Edgar Link pending
ex-311x20180331.htm Edgar Link pending
ex-312x20180331.htm Edgar Link pending
ex-321x20180331.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgls-20180331.xml Edgar Link completed
rgls-20180331.xsd Edgar Link pending
rgls-20180331_cal.xml Edgar Link unprocessable
rgls-20180331_def.xml Edgar Link unprocessable
rgls-20180331_lab.xml Edgar Link unprocessable
rgls-20180331_pre.xml Edgar Link unprocessable
rgls20180331-10q.htm Edgar Link pending
Show.js Edgar Link pending